The EU’s still-new regulations for medical devices and in vitro diagnostics are often seen as drivers of current or impending shortages of these products, but Oliver Eikenberg of regulatory ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

News Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies? Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medicatio ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

This all-encompassing guide investigates the smart insulin pen and its influence on diabetes management. Here's what you need ...

Weight loss interventions are associated with improvement in some features of polycystic ovary syndrome (PCOS).

GLP-1 receptor agonist use in the perioperative period should be based on shared decision-making of patient and care teams ...

In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s ...

Among privately insured patients, there was a doubling in the use of GLP-1 RAs as antiobesity treatment from 2022 to 2023, with a simultaneous 25.6% decrease in the rate of metabolic bariatric surgery ...

Still, gross spending on the drugs increased by more than 500% from 2019 to 2023, according to the health policy research firm.